KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medical Investigation / 2019 / Cilt: 3 - Sayı: 1

Serum Soluble Programme Death-1 and Programme Death- Ligand 1 Identify Multiple Myeloma Patients: Serum sPDL-1 May Be a Prognostic Marker

Özgür MEHTAP
Esra TERZİ DEMİRSOY
Elif BİRTAS ATEŞOĞLU
Pınar TARKUN
Ayfer GEDUK
Abdullah HACIHANEFİOĞLU
Sayfa
23–31
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Patients with high serum sPDL-1 level were associated with a significantly decreased progression freesurvival (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Multiple myeloma (MM) is a plasma cell malignancy that still remains incurable.
📊
Temel Bulgular & Veri:Programmed celldeath(PD)-1 and programmed cell death ligand (PDL-1) pathway are immune checkpoint molecules.
💡
Sonuç & Katkı:Patients with high serum sPDL-1 level were associated with a significantly decreased progression freesurvival (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: Multiple myeloma (MM) is a plasma cell malignancy that still remains incurable. Programmed celldeath(PD)-1 and programmed cell death ligand (PDL-1) pathway are immune checkpoint molecules. They play a role inthe immune escape of tumor cells.Methods: We measured serum soluble PD-1(sPD-1) and soluble PDL-1 (sPDL1) in 24 newly dignosed patients and 22healthy controls (HC).Results: We determined significantly increased serum sPDL-1 levels in MM patients when compared to HC. Moreover,sPDL-1 levels correlated positively with a p53 positive mutation status, elevated lactate dehydrogenase, C-reactiveprotein, calcium levels and poor performance status. A significant difference is detected between sPDL-1 level and PFS;but not OS. The sPDL-1 cut-off value for predicting survival outcomes was 1.03 ng/mL that was detected median valuein MM patients. Patients with high serum sPDL-1 level were associated with a significantly decreased progression freesurvival (p

🔖

Bu Makaleye Atıf Yap

MEHTAP, Ö., DEMİRSOY, E. T., ATEŞOĞLU, E. B., TARKUN, P., GEDUK, A., HACIHANEFİOĞLU, A. (2022). Serum Soluble Programme Death-1 and Programme Death- Ligand 1 Identify Multiple Myeloma Patients: Serum sPDL-1 May Be a Prognostic Marker. Eurasian Journal of Medical Investigation, Cilt: 3 - Sayı: 1, 23–31. https://ajindex.com/articles/508730

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3–9
  2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20
  3. Majithia N, Vincent Rajkumar S, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol. 2015;90:981–5
  4. Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E, Vanderkerken K. The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res. 2011;110:19–42
  5. Yang WC, Lin SF. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int 2015;341430
  6. Merelli B, Massi D, Cattaneo L, Mandalà M.Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014;89:140–65
  7. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ et al. Cancer exome analysis reveals a T-celldependent mechanism of cancer immunoediting. Nature 2012;482:400–4
  8. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64
  9. Afreen S, Dermime S.The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. Hematol Oncol Stem Cell Ther 2014;7:1–17
  10. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008;181:6738–46
  11. Matsumoto K, Inoue H, Nakano T, Tsuda M, Yoshiura Y, Fukuyama S, et al. B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. J Immunol 2004;172:2530–41
  12. Birtas Atesoglu E, Tarkun P, Demirsoy ET, Geduk A, Mehtap O, Batman A, et al. Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP): Potential Involvement of PD-1 Pathway in ITP Immunopathogenesis. Clin Appl Thromb Hemost 2016;22:248–51
  13. Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol 2013;6:74
  14. Bryan LJ, Gordon LI.Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy. Blood Rev 2015;29:25– 32
  15. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smi